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Background: Copy number variants (CNVs) are a well-recognized cause of genetic disease; however, methods for
their identification are often gene-specific, excluded as ‘routine’ in screens of genetically heterogeneous disorders,
and not implemented in most next-generation sequencing pipelines. For this reason, the contribution of CNVs to
non-syndromic hearing loss (NSHL) is most likely under-recognized. We aimed to incorporate a method for CNV
identification as part of our standard analysis pipeline and to determine the contribution of CNVs to genetic
hearing loss.
Methods: We used targeted genomic enrichment and massively parallel sequencing to isolate and sequence all
exons of all genes known to cause NSHL. We completed testing on 686 patients with hearing loss with no
exclusions based on type of hearing loss or any other clinical features. For analysis we used an integrated method
for detection of single nucleotide changes, indels and CNVs. CNVs were identified using a previously published
method that utilizes median read-depth ratios and a sliding-window approach.
Results: Of 686 patients tested, 15.2% (104) carried at least one CNV within a known deafness gene. Of the 38.9%
(267) of individuals for whom we were able to determine a genetic cause of hearing loss, a CNV was implicated in
18.7% (50). We identified CNVs in 16 different genes including 7 genes for which no CNVs have been previously
reported. CNVs of STRC were most common (73% of CNVs identified) followed by CNVs of OTOA (13% of CNVs
identified).
Conclusion: CNVs are an important cause of NSHL and their detection must be included in comprehensive genetic
testing for hearing loss.Background
Copy number variants (CNVs) are genomic variants that
alter the diploid state of a portion of the genome, either
by increasing (duplications, triplications) or decreasing
(deletions) the number of alleles. CNVs range in size
from 50 bp, the size of a small exon, to 5 megabases, the
limit of detection for cytogenetic microscopy; they there-
fore span the continuum of genetic variation between
small insertions and deletions (indels) to large chromo-
somal alterations [1]. CNVs can be benign or pathogenic,* Correspondence: richard-smith@uiowa.edu
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in copy number of dosage-sensitive genes, 2) gene disrup-
tion, or 3) fusion events leading to novel genes [2].
Whereas the mechanism of formation of single nu-
cleotide mutations or indels is errors of DNA replication
and repair, genomic rearrangements that produce CNVs
are driven primarily by genomic architecture [2]. CNVs
can be categorized by mechanism of formation, which
in turn defines characteristics specific to CNVs, such as
breakpoints and recurrence likelihood. Three mechanisms
of formation have been described and shown experimen-
tally to account for the vast majority of CNVs in the hu-
man genome: 1) non-allelic homologous recombination
(NAHR), caused by segmental duplications or repetitive
elements such as Alu or L1 repeats and leading to recur-
rent CNVs, 2) non-homologous end-joining (NHEJ), me-
diated in some instances by repetitive elements andLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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and template switching (FoSTeS), leading to non-recurrent
CNVs (reviewed in [2]).
The growing appreciation of the importance CNVs in
human disease reflects our better understanding of their
formation and improved tools for their identification.
The Human Gene Mutation Database contains 148,413
reported disease-causing mutations in 6,137 genes [3]
(accessed February 2014). Of these mutations, 89.6% are
single nucleotide changes and small (< 20 bp) indels. The
remaining 15,072 (11.4%) are structural variants that in-
clude 10,968 deletions, 2,600 insertions, and 1,504 complex
rearrangements. Examples of the contribution of CNVs to
human genetic disease include Charcot-Marie-Tooth neur-
opathy 1A (autosomal dominant), Gaucher disease (auto-
somal recessive), hemophilia A (X-linked) and mental
retardation (complex genetics) (reviewed in [4]).
CNVs have also been identified as a cause of non-
syndromic hearing loss (NSHL), the most well-known
example being deletion of a segmental duplication re-
gion of chromosome 15 that includes the gene STRC
and causes autosomal recessive NSHL (ARNSHL) at the
DFNB16 locus [5,6] or deafness-infertility syndrome
(DIS) if the adjacent CATSPER2 gene also is involved
[7]. Amongst the 89 genes involved in NSHL (this list
includes genes that cause syndromic hearing loss that
can mimic NSHL), CNVs have been reported in 18
(Table 1). To date, however, there have been more than
1,000 reported causative single nucleotide variants and
indels in these same genes [8].
We suspected that CNVs are an under-recognized
cause of deafness, a limitation associated with the trad-
itional low throughput and low-resolution methods for
identification of genomic alterations. Classic methods
for CNV identification include: 1) karyotyping and fluor-
escence in situ hybridization (FISH), a method limited
to the resolution of a microscope; 2) array compara-
tive genomic hybridization (array-CGH), a commonly
used ‘high resolution’ CNV detection method that pro-
vides resolution to about 100 kb; and 3) assays such as
multiplex ligation-dependent amplification (MLPA), cus-
tomized array-CGH panels, and breakpoint mapping.
While the resolution of these last methods is outstanding,
their implementation is costly, time-consuming, and not
scalable to the genome level. Additionally, these methods
all rely on an isolated test for CNVs. The ideal genetic test
should combine single nucleotide variant detection, indel
detection and CNV identification. In this study we sought
to determine the relative importance of CNVs as a cause
of hearing loss through the use of a diagnostic platform
that allows detection of all three of these types of variants
simultaneously.
Targeted genomic enrichment coupled with massively
parallel sequencing (TGE-MPS) has revolutionized clinicalgenetic testing by enabling specific genomic regions to be
isolated, enriched and sequenced. TGE-MPS has been
successfully applied to the diagnosis of several inherited
diseases including deafness [9-11]. Following TGE, MPS
generates millions of short sequencing reads that are
mapped to the human reference genome to cover each
sequenced nucleotide hundreds to thousands of times
(referred to as fold-coverage). Variations from the ref-
erence genome are identified and annotated, and by
capitalizing on sequencing depth of coverage between
samples, alterations to the normal diploid genomic state
can be identified and changes in copy number recog-
nized (reviewed in [12]). Several groups, including ours,
have successfully used these methods for identification of
CNVs in patients with deafness and other genetic disor-
ders [10,13-15].
In this study we use TGE-MPS with integrated CNV
detection as part of a comprehensive clinical diagnostic
platform for hearing loss. We performed genetic testing
on 686 patients with hearing loss and we identified
CNVs in 16 deafness-causing genes, including 7 genes in
which CNVs have heretofore not been described. We
show that CNVs are a major contributor to hereditary
hearing loss, comprising nearly one in five of all diagno-
ses for NSHL. These data mandate the inclusion of CNV
detection as standard on all platforms used for the clin-
ical diagnosis of genetic deafness.
Methods
Subjects
Records were examined for all patients who underwent
clinical genetic testing for deafness at our laboratory
over a two-year period beginning in January 2012. Test-
ing was completed using the TGE-MPS panel we have
developed called OtoSCOPE®. We included only unique
probands by excluding familial testing and repeat testing.
No patients were excluded based on age, age of onset of
hearing loss, previous testing, or type of hearing loss.
This study was approved by the Institutional Review
Board of the University of Iowa; because it was a retro-
spective review of clinical data with a limited chance for
harm to patients, informed consent was not obtained
and instead the study was granted a full HIPAA waiver
of authorization. To ensure anonymity of patients in this
retrospective clinical study, patient information was de-
identified, including providing ages in ranges and not
identifying the sex of the patient. Our ethical approval
did not allow deposition of patient data in to a public re-
pository. This research was performed in accordance
with the Declaration of Helsinki.
Library preparation, sequencing, and bioinformatics
TGE-MPS was completed as previously described (see
[9] for details), using 3 μg of high-quality genomic DNA.
Table 1 CNVs identified to date in non-syndromic hearing loss genes and non-syndromic hearing loss mimic genes
Gene Phenotype Locus CNV type CNV size Pubmed ID
ALMS1 AS - Deletion Partial gene deletion This study
DFNA5 ADNSHL DFNA5 Complex 1.2 kb deletion with 127 bp insertion 9771715
EYA4 DCM+ NSHL, ADNSHL DFNA10 Deletion/duplication Partial gene deletion/partial gene duplication 15735644, this study
GJB2 ARNSHL, ADNSHL DFNB1/DFNA3 Deletion Partial, whole gene, and upstream regulatory region deletion 19101659, 20236118, 15994881
GJB6 ARNSHL, ADNSHL DFNB1/DFNA3 Deletion Partial, whole gene, and upstream regulatory region deletion
11896458, 11807148, 11668644,
this study
MYH9 MYH9-Disease, ADNSHL DFNA17 Deletion/duplication Partial and whole gene deletion/partial gene duplication 18284620, this study
MYO6 ARNSHL, ADNSHL DFNB37/DFNA22 Deletion Partial gene deletion This study




Partial or whole gene deletion/partial gene duplication/pseudogene conversions 19888295, this study
OTOF ARNSHL DFNB9 Deletion Partial gene deletion 20211493
PCDH15 USH1, ARNSHL DFNB23/USH1F Deletion/duplication Partial gene deletion/partial gene duplication 20538994, 16679490, 17277737
PDZD7 USH2 modifier - Deletion Partial gene deletion This study




Deletions and rearrangements of upstream regulatory regions
20412083, 16365218, 8872461,
19930154, 20668882
SERPINB6 ARNSHL - Deletion Partial gene deletion This study
SLC26A4 PDS, ARNSHL DFNB4/PDS Deletion Partial gene deletion
17443271, 18285825, 19287372,
19287372, 12676893, this study
STRC ARNSHL, DIS DFNB16
Deletion/duplication/
conversion
Whole gene deletions/whole gene duplications/pseudogene conversions 11687802, 17098888, this study
TECTA ARNSHL DFNB21/DFNA8/DFNA12 Deletion Partial gene deletion 17431902
TJP2 ADNSHL DFNA51 Duplication Tandem inverted duplication of entire gene 20602916
TMC1 ARNSHL DFNB7/DFNB11/DFNA36 Deletion Partial gene deletion 11850618, 19187973, this study
TMPRSS3 ARNSHL DFNB8/DFNB10 Deletions/complex Partial gene deletion/complex microsatellite insertion 11137999, this study




DFNB18/USH1C Deletion Whole gene deletion 10973248
USH2A USH2 - Deletion Partial gene deletion This study
WFS1 DIDMOAD, ADNSHL DFNA6/DFNA14 Deletion/duplication Partial gene deletion/partial gene duplication 15277431, this study
Abbreviations: ADNSHL, autosomal dominant nonsyndromic hearing loss; ARNSHL, autosomal recessive nonsyndromic hearing loss; AS, Alström syndrome; DCM, dilated cardiomyopathy; DIDMOAD, aka Wolfram
syndrome, diabetes insipidus, diabetes mellitus, optic atrophy, and deafness - autosomal recessive; DIS, deafness-infertility syndrome - autosomal recessive; PDS, Pendred syndrome, deafness, inner ear abnormalities,
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pare the majority of libraries. We used OtoSCOPE v4 or
v5, targeting 66 or 89 deafness-associated genes, respect-
ively. We used v4 for 76 and v5 for 28 of the patients for
whom we found CNVs, respectively (Additional file 1).
We include all NSHL genes known at the time each re-
spective version of OtoSCOPE was made (v4 designed
May 2011, and v5 designed November 2012) as well as
genes that cause syndromic forms of deafness that mimic
NSHL at an early age. In addition to the inclusion of newly
discovered NSHL genes, OtoSCOPE v5 also includes sev-
eral more NSHL mimics and additional probe coverage
over the extended OTOA genomic region as well as the
STRC genomic region to improve our ability to delimit the
size of copy number variants at these loci. We also added
probes to cover the gene CATSPER2, which is upstream of
STRC and often involved in CNVs at this locus.
Sequencing was performed in pools of up to 48 samples
per Illumina HiSeq flow cell using 100-bp paired-end
reads. Sample quality control values were maintained as
described previously [9]. All samples either met these re-
quirements or were re-run.
Data were analyzed using a local installation of the
open-source Galaxy software [16,17] and a combination
of several other open-source tools, including read mapping
with Burrows-Wheeler Alignment (BWA) [18], duplicate
removal with Picard, local re-alignment and variant calling
with GATK Unified Genotyper [19], enrichment statistics
with NGSRich [20], and reporting and annotation of vari-
ants with custom software [9].
For copy number analysis, we completed read mapping,
duplicate removal, and re-alignment as described above.
Next we used the indexed BAM file to call variants and
generate a pileup using samtools [21] mpileup –Bf, retain-
ing only the position and depth information for all
variants called. We then performed CNV calling using
a previously published tool written in R [22]. This method
normalizes read-depth data by sample batch and com-
pares median read-depth ratios using a sliding-window
approach [22]. This tool is available by request from the
original author (A Nord, personal communication). We
performed this analysis using the 2011-07-01 version of
the tool with default settings. CNV calls were curated
through manual inspection.
We validated this method using MLPA spanning the
STRC gene region on chromosome 15q15.3 [23]. Our
validation set of samples included DNA from 60 GJB2
negative probands with NSHL and 4 positive control in-
dividuals simultaneously tested with TGE-MPS and
blinded MLPA testing. Results showed four homozygous
deletions and four heterozygous deletions of this region
with 100% concurrence between the methods.
All variant calls, including SNVs, indels and CNVs, were
discussed at an interdisciplinary meeting (Hearing GroupMeeting) that includes physicians, geneticists, genetic
counselors, scientists and bioinformaticians. At these
meetings, all available clinical, phenotypic and genetic data
are used to determine the most likely genetic cause, if any,
for hearing loss.
Results
Copy number variants identified
We identified 143 CNVs in 16 genes in 686 patients with
hearing loss (Table 2; Additional file 2). Of the patients
studied, 15.2% (104/686) carried at least one CNV in a
known deafness gene. We report CNVs in 7 of these
genes for the first time, increasing the number of known
deafness genes with CNVs by 28% to 25 total genes
(Table 1). The overall CNV carrier frequency was 20.8%
(143 CNVs/686 patients). We identified a probable genetic
cause of hearing loss, be it a single nucleotide variant,
indel, or CNV, in 38.9% of patients enrolled in this study
(267/686). Detailed diagnostic results for these patients
not pertaining to CNVs will be reported elsewhere.
Eighty-six CNVs were identified and considered causa-
tive in 18.7% (50/267) of diagnosed patients. Of these
patients, the causative CNVs were categorized as follows:
21 (42%) homozygous CNVs (all deletions), 16 (32%)
hemizygous CNVs found in conjunction with a second
pathogenic change, 12 (24%) biallelic CNVs, and 2 (4%)
CNVs that are part of a large heterozygous contiguous
deletion of chromosome of at least 1.5 Mb on chromo-
some 22q12.3-22q13.1 in one patient (Additional file 2).
Homozygous CNVs are defined as the same change to
copy number on both alleles while biallelic mutations are
defined as a different copy number change on each allele
(that is, a gene deletion and a gene conversion).
Of 50 patients with causative CNVs, 48 were diagnosed
with ARNSHL. Two patients segregated apparent auto-
somal dominant NSHL (ADNSHL), one of whom carried
both a single nucleotide mutation in DIAPH1 predicted to
be pathogenic as well as a large heterozygous deletion of
chromosome 22q12.3-22q13.1 of approximately 1.5 Mb
that includes both MYH9 and TRIOBP. The extent of this
deletion could not be resolved further due to the lack of
other targeted genes on this chromosome. In this patient
either the large CNV or the mutation in DIAPH1 may be
responsible for the hearing loss. The size of the deletion
and the absence of additional phenotypic data make a
more definitive interpretation of these variants difficult. A
subtle syndromic form of deafness is also possible. This
patient was the only case in which two possible deafness-
causing variants were identified.
The second patient segregating ADNSHL had mod-
erate hearing loss and an out-of-frame deletion of the
last 12 exons ofMYO6 predicted to be causative (Additional
file 2). A deletion in TMC1, which can cause both
ARNSHL and ADNSHL at the DFNB7/11 and DFNA36
Table 2 Summary of all CNVs identified in 686 individuals requesting genetic testing for deafness using a
comprehensive genetic testing platform
Gene Total CNVs Carrier CNVs Causative CNVs (%) Deletions (%) Conversions (%) Duplications (%)
STRC 105 (73%) 35 (61%) 70 (81%) 65 (71%) 35 (92%) 5 (38%)
OTOA 18 (13%) 11 (19%) 7 (8%) 12 (13%) 3 (8%) 3 (23%)
GJB6 4 (3%) 1 (2%) 3 (3%) 4 (4%) - -
USH2A 3 (2%) 2 (4%) 1 (1%) 2 (2)% - 1 (8%)
MYH9 2 (1%) 1 (2%) 1 (1%)a 1 (1%) - 1 (8%)
ALMS1 1 (1%) 1 (2%) - 1 (1%) - -
MYO6 1 (1%) 1 (2%) - 1 (1%) - -
PDZD7 1 (1%) 1 (2%) - 1 (1%) - -
SERPINB6 1 (1%) 1 (2%) - 1 (1%) - -
SLC26A4 1 (1%) - 1 (1%) 1 (1%) - -
TMC1 1 (1%) - 1 (1%) 1 (1%) - -
TMPRSS3 1 (1%) - 1 (1%) 1 (1%) - -
TRIOBP 1 (1%) - 1 (1%)a 1 (1%) - -
EYA4 1 (1%) 1 (2%) - - - 1 (8%)
WFS1 1 (1%) 1 (2%) - - - 1 (8%)
PNPT1 1 (1%) 1 (2%) - - - 1 (8%)
Total 143 57 86 92 38 13
See Additional file 2 for details. aPart of a large CNV encompassing at least 1.5 MB (see text for details).
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a second missense variant in a patient with ARNSHL. The
only other CNV present in a gene implicated in ADNSHL
was an in-frame duplication of exons 18 to 20 of EYA4.
Mutations in EYA4 cause ADNHSL at the DFNA10
locus. For this study we categorized this CNV as non-
pathogenic, although further study is required to deter-
mine whether this CNV is translated and pathogenic
through a dominant-negative effect.
Most CNVs were deletions (92, 64.3%), followed by
gene conversions (38, 26.6%), and duplications (13, 9.1%)
(Table 2). The CNVs we detected ranged in size from one
exon to over 1.5 Mb (chromosome 22q12.3-22q13.1).
The genomic architecture of hearing loss genes
To define the landscape of repeat elements that sur-
round known NSHL genes, we performed a bioinformat-
ics analysis of segdups (segmental duplications), Alu
elements and L1 elements as these elements are sites of
NAHR and mediate NHEJ [2]. Using data from Repeat-
Masker [24] we examined the presence of these repetitive
elements within known deafness genes. Segdups, defined as
regions with > 95% homology, are features that are causally
implicated in recurrent CNVs mediated by NAHR and
were identified in seven deafness genes: TSPEAR (4 segd-
ups), OTOA (1), STRC (1), MYO3A (1), ESPN (1), OTOGL
(1), CACNA1D (1). Both OTOGL and CACNA1D have
homology to regions on different chromosomes, which pre-
disposes to inter-chromosomal translocation via NAHR.Alu and L1 elements are smaller repetitive elements
and predispose to recurrent NAHR and non-recurrent
NHEJ. Only six genes on our panel lacked Alu or L1 ele-
ments, and when we normalized the number of these el-
ements by gene size, we found significantly more Alu
elements, L1 elements, and total Alu + L1 elements in
CNV-associated genes (paired t-test, P = 0.0003, P =
0.0104, P = 0.0139, respectively; Additional file 3). In
contrast, a comparison of all simple repeat elements
normalized per gene found no significant difference be-
tween the 16 CNV-associated genes and the remaining
genes on our panel (P = 0.6442), suggesting that the in-
creased repetitive element burden could explain, at least
in part, the gene distribution of CNVs we observed.
To illustrate the impact of CNV identification in the
genetic evaluation of NSHL, we present three represen-
tative cases below.
Biallelic conversion of the STRC gene
Patient 45 was evaluated for mild sensorineural hearing
loss (SNHL) after failing the newborn hearing screen
(NBHS). A diagnostic auditory brainstem response (ABR)
at 4 weeks showed bilateral mild hearing loss and the pa-
tient was fitted with binaural amplification. There was no
family history of hearing loss.
TGE-MPS identified a biallelic partial gene conversion
involving STRC and the pseudogene, ψSTRC. As shown
in Figure 1, the last 11 exons of STRC have been con-
verted to ψSTRC leading to a functionally null STRC.
Figure 1 A biallelic gene-pseudogene conversion of STRC is the causative mutation in patient 45. (a) Ratio plots showing apparent
homozygous deletion of first 11 exons of STRC and duplication of first 11 exons of ψSTRC. (b) Hypothesized mechanism of gene-pseudo-gene
conversion (non-allelic gene conversion in trans) and depiction of the biallelic change in the patient.
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gene-pseudogene conversion at this locus. STRC encodes
stereocilin, which localizes to the tips of outer-hair-cell
stereocilia where it is hypothesized to form tip-link con-
nectors between stereocilia as well as part of the connec-
tion between outer hair cells and the tectorial membrane
[25]. Its mutation causes mild hearing loss. Additionally,
because the STRC gene region is associated with a segdup
that results in pseudogenes of both STRC and CATSPER2,
homozygous deletions of the entire region (STRC and
CATSPER2) cause DIS, characterized by mild SNHL in
males and females and sperm motility defects and infertil-
ity in males [7].In our cohort of 686 patients, we identified causative
mutations in STRC, including homozygous deletions, gene
conversions, and heterozygous deletions in trans to a mis-
sense change, in 5.4% of patients (37/686; Table 2), ac-
counting for 13.8% of all genetic diagnoses we provided
(37/267) and making mutations in STRC one of the most
common causes of ARNSHL, following closely behind mu-
tations in GJB2 in primarily Caucasian populations. The
carrier frequency for deletions, conversions, and duplica-
tions at the STRC locus was 4.7% (65/1,372 alleles), 2.6%
(35/1,372 alleles), and 0.4% (5/1,372 alleles), respectively.
Forty-six patients carried at least one deletion in the
STRC gene region (Additional file 2). We were able to
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these patients because they were tested with OtoSCOPE
v5 (Materials and methods; Additional file 1). We found
that the CATSPER2 gene was involved in 77.0% (10/13)
of these patients, including one individual in which the
deletion encompassed only CATSPER2 and ψSTRC and
not STRC. Four individuals were homozygotes for a large
contiguous STRC-ψSTRC-CATSPER2 deletion, indicating
that they in fact are affected by DIS and not NSHL. All
four of these patients are female and therefore will not
have decreased fertility.
Deletion of OTOA in a Caucasian individual
Patient 14 was diagnosed with congenital moderate-to-
severe SNHL after failing the NBHS, tested with otoacous-
tic emissions. A diagnostic ABR at 6 weeks confirmed the
hearing loss and the patient was fitted with binaural amp-
lification. There was no family history of hearing loss. The
patient’s ethnicity was European-American.
TGE-MPS identified a homozygous deletion of the en-
tire OTOA gene and the patient was diagnosed with
DFNB22-related hearing loss (Figure 2). OTOA encodes
otoancorin, an extracellular membrane protein that lo-
calizes to the interface between the tectorial membrane
and the sensory epithelium [26]. It contains a glycopho-
sphatidylinositol anchor that is thought to mediate attach-
ment between the tectorial membrane and the greater
epithelial ridge and spiral limbus during development, and
with the spiral limbus in the mature cochlea. Mice lacking
Otoa have hearing loss secondary to an abnormality of the
tectorial membrane, which is attached at to the outer hair
cells but detached from the spiral limbus [27].
To date, three mutations in OTOA have been reported
within the Palestinian population: IVS12(+2)T > C [26],
c.1067A > T, p. D356V [28], and a 500 kb deletion [29].
Two pathogenic OTOA mutations were recently discov-
ered in the Pakistani population: p.G451D and p.P627S
[30]. The deletion we report here is therefore the first re-
port of a mutation in OTOA in a person of non-Middle-
Eastern ethnicity. We identified 18 CNVs involving OTOA,
including 15 deletions, 3 conversions and 3 duplications,
making CNVs of OTOA the second most commonly iden-
tified CNVs after STRC. This frequency likely reflects theFigure 2 Ratio depth-of-coverage plot showing homozygous deletion
exons appear to be only heterozygous deletion, but this is an artifact due tfact that exons 20 to 28 are part of a segdup of > 99%
identity located 820 kb away [29]. In five cases, including
this example, the CNV was causative.
A two exon deletion in TMC1
Patient 100 failed the NBHS and was subsequently diag-
nosed with profound, symmetric NSHL by follow-up ABR.
There was no reported family history of hearing loss. TGE-
MPS identified an incidental heterozygous change in GJB2
(c.101 T >C p.M34T) and a heterozygous two-exon dele-
tion (exons 14 and 15) of TMC1 (Figure 3). Although the
precise breakpoints could not be determined, the CNV
encompasses the entirety of exons 14 (145 bp) and 15
(195 bp) and intron 14, making it between 1 and 20 kb in
size (Figure 3). The deletion is out of frame and segre-
gates opposite a c.545G >A p.Gly182Asp missense change
in exon 11. Pathogenicity software shows this missense
change to be damaging or deleterious by six in silico scor-
ing methods (SIFT, PhyloP, Polyphen, LRT, MutationTaster,
and GERP; see [9] for details) and thus is predicted to be
pathogenic. The variant has a reported frequency in the
Exome Variant Server of 0.000154.
Mutations in TMC1 cause ARNSHL at the DFNB7/11
loci and ADNHSL at the DFNA36 locus [31]. More than
35 mutations have been reported as deafness causing
[32,33], including two large deletions leading to DFNB7/
11-related hearing loss [31,34]. This patient therefore
carries the third deletion of this gene to be associated
with NSHL and is the first report of a hemizygous dele-
tion opposite a missense mutation.
Discussion
In this study, we performed comprehensive genetic testing
of 686 patients with NSHL and showed that CNVs are a
common contributor to hearing loss. We identified 143
CNVs in 16 deafness genes, including in 7 genes in which
CNVs have not been reported (Table 1). Nearly one in three
deafness genes (25 of 89 genes, 28%) carried a CNV and in
aggregate CNVs contributed to nearly one in five (18.7%)
genetic diagnoses for NSHL. These results mandate CNV
screening in all comprehensive genetic testing platforms for
deafness. Ideally, CNV detection should be incorporated
in the diagnostic pipeline as a single test, which weof OTOA as the causative mutation in patient 14. The last 10
o segmental duplication of these exons (see text for details).
Figure 3 A two-exon deletion of TMC1 is responsible for deafness in patient 100. (a) Ratio depth-of-coverage plot showing a two-exon
heterozygous deletion. This deletion was found in trans with a missense change predicted to be pathogenic (c.1276G > A, p.Ala426Thr). (b)
Highlighted region from UCSC genome browser RepeatMasker track demonstrates multiple short interspersed elements (SINEs; primarily Alu
repeats), long interspersed elements (LINEs; including L1 repeats), and long terminal repeats (LTR) in this region. The two deleted exons are
marked with asterisks. The hypothesized mechanism for this deletion involves these repeat elements and NAHR.
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proach for variant detection to our TGE-MPS platform.
NAHR, the primary mechanism of formation of recur-
rent CNVs, is generally mediated by segdups or low-copy
repeats [2]. Segdups range in size from 10 to 300 kb and
typically must have > 95% homology for recombination to
occur. Depending on the orientation of the segdup, an
NAHR event can lead to duplications and deletions (segd-
ups in parallel), inversions (segdups in opposition), or
translocations (segdups on different chromosomes). NHEJ
and FoSTeS, in comparison, are mediated by smaller re-
petitive elements, including short interspersed elements
(SINES) such as Alu elements, and long interspersed
elements (LINES) such as L1 repeats. Because NHEJ is
dependent on repair of double-strand breaks, it leaves a
signature ‘scar’ at the point of the repair. FoSTeS occurs
during DNA replication and causes deletions, duplications
and, when multiple FoSTeS events occur in sequence,
complex rearrangements. ‘Joint points’, repetitive elements
and regions of microhomology of 2 to 3 bp are often the
sites of FoSTeS.
The greatest number of CNVs was identified in STRC
and OTOA, comprising 73% and 13% of all CNVs identi-
fied, respectively (Table 2). These two genes contain
NAHR-predisposing segdups. We also identified segdups
in TSPEAR, MYO3A, ESPN, OTOGL and CACNA1D,
five genes in which CNVs have not been reported. In
genes carrying CNVs in this study, we found a significantly
higher number of small repetitive elements. We also iden-
tified several genes highly enriched for repetitive ele-
ments and thus likely candidates for CNVs (MARVELD2,
CCDC50, LHFPL5, DIABLO, SLC26A5; see Additional
file 3 for a full list).
Although our TGE-MPS platform precludes the deter-
mination of breakpoints, we obtain outstanding exon-
level resolution for CNV detection and can identifyCNVs, single nucleotide changes and indels simultan-
eously. By tiling probes across pseudogenes in segdups
we are able to reliably determine gene conversions and
thereby improve our diagnostic ability.
The carrier frequency of the most common CNV, a
deletion of the STRC region, was 4.7% in this study. Pre-
vious studies of patients with hearing loss using less sen-
sitive SNP arrays for CNV detection have found carrier
frequencies of 1.8% (659 patients) [6] and 6.4% (94 pa-
tients) [35]. Two other studies using array CGH re-
ported a carrier frequency in individuals without hearing
loss undergoing genetic testing for other reasons to be
1.1% and 1.6% [23,36]. These data suggest that, in some
populations, the carrier frequency of deletions of the
STRC region may be more common than the carrier fre-
quency of the most common mutations in GJB2. However,
it is also important to consider the potentially pathogenic
gene-pseudogene conversions at this locus. In this study
we found the carrier frequency of these conversions to be
2.6%. Other platforms may not be able to accurately detect
these potentially pathogenic conversions and so the carrier
frequency for deleterious CNVs of this region is most
likely under-reported.
Deletions of the STRC region are especially import-
ant to detect because concurrent deletion of the adja-
cent CATSPER2 gene leads to DIS in males [7]. In those
patients for whom we used the modified version of our
panel that includes the CATSPER2 gene, we identified its
involvement in 10/13 cases with STRC deletion, suggest-
ing that DIS is likely an under-diagnosed cause of hearing
loss and male infertility.
This study has three minor limitations. First, the
samples we studied were submitted for clinical testing
and therefore detailed family history, clinical and/or
phenotypic data were not available, precluding robust
genotype-phenotype correlations and decreasing certainty
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evaluate the carrier frequency of these CNVs in a control
population, which remains an area of future study. And
last, we used TGE-MPS for CNV detection, making it im-
possible to map breakpoints that occur outside targeted
exonic regions. This constraint means that if a CNV spans
multiple genes, it is impossible to determine its approxi-
mate size. However, when commonly occurring CNVs
are recognized, additional probes can be added to any
TGE-MPS platform to increase information content. For
example, we have included more probes for the STRC/
CATSPER2 region in recent versions of the platform used
here.
Conclusion
CNVs are a common cause of NSHL. Their involvement
in one in five genetic diagnoses by our laboratory using
a comprehensive genetic testing platform mandates their
identification in any clinical genetic diagnostic test for
deafness. These data suggest that CNVs are likely to play
an important role in other genetic disorders as well.
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